- Q2 2024 Cue Biopharma Inc Earnings Call Transcript6 days ago€0.585 (+9.35%)Earnings
- Q4 2023 Cue Biopharma Inc Earnings Call TranscriptApr 08, 2024€1.7 (+4.94%)Earnings
- Q3 2023 Cue Biopharma Inc Earnings Call and Business Update TranscriptNov 09, 2023€2.24 (-4.36%)Earnings
- Q2 2023 Cue Biopharma Inc Earnings Call TranscriptAug 09, 2023€3.2 (+3.16%)Earnings
- Cue Biopharma Inc To Host Business Update Call TranscriptJun 14, 2023
- Cue Biopharma Inc at Jefferies Healthcare Conference TranscriptJun 09, 2023
- Cue Biopharma Inc at JMP Securities Life Sciences Conference TranscriptMay 15, 2023
- Q4 2022 Cue Biopharma Inc Earnings Call TranscriptMar 21, 2023€2.86 (+2.14%)Earnings
- Q3 2022 Cue Biopharma Inc Earnings Call TranscriptNov 14, 2022€3Earnings
- Q2 2022 Cue Biopharma Inc Earnings And Business Update Call TranscriptAug 23, 2022
- Cue Biopharma Inc at JMP Securities Life Sciences Conference TranscriptJun 16, 2022
- Cue Biopharma Inc To Host Business Update And Ongoing CUE-101 Clinical Trials Call TranscriptJan 26, 2022
- Q2 2021 Cue Biopharma Inc Earnings Call TranscriptAug 17, 2021€8.45 (-8.65%)Earnings
- Q1 2021 Cue Biopharma Inc Earnings Call TranscriptMay 17, 2021€11.1 (+5.71%)Earnings
- Q4 2020 Cue Biopharma Inc Earnings Call TranscriptMar 16, 2021€12.5 (+5.93%)Earnings
- Cue Biopharma Inc at Cowen Healthcare Conference (Virtual) TranscriptMar 04, 2021
- Cue Biopharma, Inc. - Special Call TranscriptNov 17, 2020
- Cue Biopharma Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 17, 2020
- Q2 2020 Cue Biopharma Inc Earnings Call TranscriptAug 31, 2020€14.7 (-1.34%)Earnings
- Q1 2020 Cue Biopharma Inc Earnings Call TranscriptMay 19, 2020€24Earnings
- Q4 2019 Cue Biopharma Inc Earnings Call TranscriptMar 17, 2020€11.6Earnings
- Cue Biopharma, Inc. - Special Call TranscriptNov 12, 2019
- Cue Biopharma Inc Investor Business Update TranscriptMay 21, 2019
- Cue Biopharma, Inc. - Special Call TranscriptMar 14, 2019
Q2 2022 Cue Biopharma Inc Earnings And Business Update Call Transcript
Greetings, and welcome to the Cue Biopharma update call. (Operator Instructions). As a reminder, this conference is being recorded.
I would now like to turn this conference over to Mr. Dan Passeri, Cue Biopharma's Chief Executive Officer. Thank you, sir. You may begin.
Okay. Thank you, and good afternoon, everyone. Just to remind you, as we proceed through the presentation, we'll convey which slide we're on, and you can advance the slides directly. We appreciate your time and interest in our update call regarding our ongoing trials of CUE-101 as well as CUE-102, our initial representative drug candidates of the IL-2-based CUE-100 series.
Joining me on today's call is Dr. Anish Suri, our President and Chief Scientific Officer; Dr. Ken Pienta, our Acting Chief Medical Officer; and Dr. Matteo Levisetti, our Senior Vice President of Clinical Development; and Kerri Millar, our Chief Financial Officer. This conference is being recorded and will be available on our website for the next 30
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)